Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced NRAS-Mutant Solid Tumors”

5 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 5 of 5 results

Early research (Phase 1)Study completedNCT03415126
What this trial is testing

ASN007 in Patients With Advanced Solid Tumors

Who this might be right for
CancerMalignancyNeoplasia+16 more
Asana BioSciences 49
Testing effectiveness (Phase 2)Ended earlyNCT03637491
What this trial is testing

Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors

Who this might be right for
Pancreatic Cancer
Pfizer 36
Early research (Phase 1)Looking for participantsNCT07584226
What this trial is testing

A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors

Who this might be right for
Advanced NRAS-Mutant MelanomaAdvanced NRAS-Mutant Solid TumorsNRAS Mutation+8 more
Relay Therapeutics, Inc. 35
Testing effectiveness (Phase 2)Study completedNCT06208124
What this trial is testing

IMM-6-415 in RAS/RAF Mutant Solid Tumors

Who this might be right for
Advanced Solid Tumor (Phase 1)Pancreas AdenocarcinomaNon-small Cell Lung Cancer+1 more
Immuneering Corporation 30
Early research (Phase 1)Ended earlyNCT03114319
What this trial is testing

Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors

Who this might be right for
Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC)KRAS G12-mutant NSCLCEsophageal Squamous Cell Cancer (SCC)+4 more
Novartis Pharmaceuticals 227